The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe

in acute coRonary syndrome (HIJ-PROPER)

Purpose: In a Japanese patient population with acute coronary syndrome (ACS) and
dyslipidemia, to evaluate whether cardiovascular events are lower with intensive LDL-C lowering
(standard statin dose + ezetimibe) vs. standard dosing alone.
Trial Design: n= 1734; open-label, blinded, multi-center Japanese study; 3 year f/u; randomized
to intensive LDL-C lowering treatment (LDL-C target <70 mg/dL; pitavastatin + ezetimibe) or
standard LDL-C lowering treatment (LDL-C target 90100 mg/dL; pitavastatin alone).
Primary Endpoint: Adverse event composite (total all-cause death, non-fatal MI and stroke,
unstable angina, revascularization).
Trial Results

% Reduction in adverse events

pitavastatin + ezetimibe

32.8%

pitavastatin

36.9%

P value
0.152

Conclusions: The addition of a second cholesterol-lowering drug to standard statin therapy to patients
with acute coronary syndrome and dyslipidemia did not significantly improve the primary endpoint rates.

Presented by: Nobuhisa Hagiwara , ESC Congress 2016, Rome, Italy

2016, American Heart Association. All rights reserved